|
Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). |
|
|
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Bayer; Boehringer Ingelheim; Epizyme; Morphotek; Roche; Sellas Life Sciences; Trizell |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca |
|
|
Travel, Accommodations, Expenses - Boehringer Ingelheim |
|
|
Honoraria - Novartis; Pfizer |
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Boehringer Ingelheim; MSD Oncology; Pfizer |
|
|
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Novartis; Pfizer; Roche |
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Epizyme (Inst); Lilly (Inst); Roche (Inst) |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Roche |
Research Funding - Roche (Inst) |
|
|
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; AstraZeneca/MedImmune; Pfizer; Roche/Genentech |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Roche |
|
|
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck; MSD; Novartis; Pfizer; Proacta |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck; MSD; Novartis; Pfizer; Roche |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck; MSD; Novartis; Pfizer; Roche |
|
|
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Merck Serono; Novartis; Pfizer; Roche; Specialised Therapeutics |
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Merck Serono; Novartis; Pfizer; Roche; Sanofi; Specialised Therapeutics |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Merck; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi |
Research Funding - Novartis (Inst) |
|
|
|
|
Brett Gordon Maxwell Hughes |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
|
|
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
|
|
|
Consulting or Advisory Role - Genentech |
Research Funding - Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Boehringer Ingelheim |
|
|
Employment - Boehringer Ingelheim |
|
|
Honoraria - AstraZeneca; Lilly; MSD; Pfizer; Roche |
Consulting or Advisory Role - Lilly |
Speakers' Bureau - Lilly; MSD |
Travel, Accommodations, Expenses - Bayer |